BLAINE, Wash., Nov. 7 /PRNewswire-FirstCall/ -- GeneMax Corp. (OTC Bulletin Board: GMXX; Frankfurt: GX1) and its patented TAP cancer therapy will be featured in a new segment in an upcoming broadcast on the ABC News Program "BusinessNOW" on Sunday, November 9, 2003. The program was originally scheduled to air Sunday, November 2, 2003 but was rescheduled by the network. The video segment is also available at the Company's website at http://www.genemax.com/.
The TV segment focuses on GeneMax's TAP cancer therapy moving toward human trials and features recent interviews with Chairman & CSO, Dr. Wilfred Jefferies and company President & CEO, Ronald Handford.
BusinessNOW airs weekly on ABC Television stations in New York and Raleigh, North Carolina, as well as on the cable television network, TECH TV. The program is a half-hour business news magazine that covers today's leading trends in business in an entertaining format that takes viewers on location.
Viewers can watch the program live as follows: Sunday, Nov. 9, 2003: WABC (New York) Channel 7 @ 10:30 AM EST.
The segment will also be available for viewing via streaming video on the ABCNews.com website after 6:00 PM EST on Saturday, November 8, 2003 at http://abcnews.go.com/sections/business/BusinessNow/BusinessNow.html .
The program will also be distributed to approximately 150 of ABC's affiliates for airing at a later date.
About GeneMax Corp.
GeneMax Corp. is a biotechnology company specializing in the discovery and development of immunotherapeutics aimed at the treatment and eradication of cancer, and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection.
SAFE HARBOR STATEMENT
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, THE COMPANY'S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN."
CONTACT: North America, Marcus Johnson, +1-866-872-0077 or+1-360-332-7734, or fax, +1-360-332-1643; or Europe, Richard Elliot-Square,41 43.888.67.00, or fax, 41.43.888.67.09, both for GeneMax Corp.